Pediatric Obesity Management Market Size to Hit US$ 4.37 Billion by 2031 | Growth Plus Reports


Newark, New Castle, USA, June 14, 2023 (GLOBE NEWSWIRE) — The market analysis of the global pediatric obesity management market was conducted by Growth Plus Reports in 2022 and is valued at US$ 3.02 billion. The market is expected to hit a revenue CAGR of 4.2% to reach US$ 4.37 billion by 2031.

Analysis of the global market for pediatric obesity management indicates that during the forecast period, revenue share is likely to increase significantly. Therapeutics for pediatric obesity management include drugs or dietary additions that are used to treat childhood and adolescent obesity. 

Key Takeaways: 


  • The increasing number of children with obesity is driving the market revenue share.
  • The rising risks of diabetes and other cardiovascular disease is driving the market demand.
  • The demand for precise drug treatment is increasing the market revenue growth rapidly.

Request a Free Sample of the Research Report:

                        Pediatric Obesity Management Market Scope

Report Attribute Details
Market Size Value in 2022 US$ 3.02 billion
Revenue Forecast in 2031 US$ 4.37 billion
CAGR 4.2%
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Type, Gender, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Recent Development in the Pediatric Obesity Management Market: 

  • In December 2022, Novo Nordisk’s semaglutide (Wegovy) was given FDA approval to treat obesity in children patients 12 years of age and older.
  • In June 2022, For individuals with obesity who are of 12 years or older, the FDA authorized a new indication for phentermine and topiramate extended-release capsules (brand name Qsymia).

Competitive Landscape

A list of the companies operating in the global market for pediatric obesity management includes: 

  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • AstraZeneca 
  • Herbalife Ltd
  • Apollo Endosurgery 

Market Drivers and Restraints: 

The global pediatric obesity management market revenue is driven by the increasing measures to control childhood obesity, the demand for an effective treatment option, and the introduction of novel products in the market for curing pediatric obesity. 

However, due to the unawareness of the information and high costs of treatment, the pediatric obesity management market revenue growth is expected to be restrained. 

Market Segmentation: 

  • Based on types, the global pediatric obesity management market is segmented into medication and supplements. 
  • The medication segment is further sub-segmented into lipase inhibitors, anorectics, serotonin receptor agonists, incretin mimetics, and melanocortin 4 (MC4) receptor agonists. 
  • Based on distribution channels, the global hospital pharmacies, retail pharmacies, and online pharmacies. 

Request for Customization –

Segmentation By Type

Based on the types, the medication segment dominates the global pediatric obesity management market with the largest revenue share. This sizable share of revenue is attributed to several drugs, including orlistat (Lipase inhibitor), liraglutide (incretin mimetics), and phentermine/topiramate (Anorectics), which are the most common types of treatment options. Furthermore, the global pediatric obesity management market revenue is also accelerated by their effective results as a health supplement and negative side effects. 

Regional Growth Dynamics

Based on the region, North America, with the largest revenue share, dominates the global pediatric obesity management market. This large share of revenue is attributed to the sophisticated healthcare infrastructure with substantial public support for healthcare initiatives and expenditures in R&D. 

Report Coverage 

Global market research on the pediatric obesity management market was done in-depth by Growth Plus Reports. We looked at the core market traits, noteworthy investment prospects, regional growth trends, ten-year revenue projections, rival market participants, and mergers and acquisitions.

Table of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    4. Reimbursement Scenario 
    5. Epidemiology and Patient Population
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Medication
      1. Lipase Inhibitors
      2. Anorectics
      3. Serotonin Receptor Agonist 
      4. Incretin Mimetics 
      5. Melanocortin 4 (MC4) Receptor Agonists
    2. Supplements
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies


Buy this Premium Research Report:


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Schedule a call with our analyst:

Visit our report store at –

Browse more latest healthcare reports:

Anticholesteremic Agents Market by Drug Class (Bile Acid Resins, Statins), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Glucose Elevating Agents Market by Products (Glucagon, Diazoxide), Indication (Hypoglycemia, Insulinoma), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), – Global Outlook & Forecast 2023-2031

Expat Health Insurance Market by Service Provider (Private, Public), Indication (Emergency Medical Evacuation, Maternity Coverage, Outpatient Coverage), Term Plan (Short-Term, Long-Term) – Global Outlook & Forecast 2023-2031

Veterinary Euthanasia Drugs Market by Animal Type (Companion Animals and Farm Animals), Route of Administration (Injectable Euthanasia Drugs, Inhalational Euthanasia Drugs) – Global Outlook & Forecast 2023-2031

MISME Syndrome Market by Treatment (Surgery, Radiotherapy, Pharmacotherapy) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.

CONTACT: Manan Sethi Director, Market Insights Email: [email protected] 256 Chapman Road STE 105-4, Newark, New Castle - 19702, USA Phone no: +1 888 550 5009 Web:

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. takes no editorial responsibility for the same.